Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.07% | -36.95% | -0.62% | -1.16% | -5.78% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 321.27% | 98.02% | 87.74% | 123.21% | 35.80% |
| Change in Net Operating Assets | 93.38% | 1,041.81% | 544.31% | 490.80% | 36.80% |
| Cash from Operations | -2.04% | 2.42% | 41.98% | 21.85% | -1.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.80% | -97.50% | 20.93% | 152.23% | 121.53% |
| Cash from Investing | -100.80% | -97.50% | 20.93% | 152.23% | 121.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,509.82% | 5,164.37% | 82.64% | -90.84% | -80.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,031.25% | 6,011.49% | 201.13% | -90.84% | -80.25% |
| Foreign Exchange rate Adjustments | -187.50% | -- | 20.00% | -102.33% | -113.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.36% | -253.49% | 124.49% | 92.15% | 88.29% |